Verifying…
Home / Drug A–Z / Inkretin Tablets

Inkretin Tablets

NAFDAC Reg. No. A11-100728 · Drug

Registered with NAFDAC. Registration activeAs of 28 October 2026 · synced automatically from official sources.
Product
Inkretin Tablets
NAFDAC number
A11-100728
Active ingredient
Cyproheptadine Hydrochloride
Strength
4 mg
Form
Tablet
Pack size
1 x 30's
Manufacturer
Not listed
Applicant (holder)
Evergreen Morning Star Pharmaceutical Ind. Ltd
Approved
27 Jun 2024
Status
Active View on NAFDAC ↗
Registration valid to
26 Jun 2029
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Inkretin Tablets is on the NAFDAC register with an active registration (A11-100728). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

What Inkretin Tablets is used for

From the official U.S. FDA label for cyproheptadine hydrochloride, the active ingredient registered with NAFDAC.

What it is used for

Perennial and seasonal allergic rhinitis, Vasomotor rhinitis, Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Cold urticaria. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Possible side effects

Adverse reactions which have been reported with the use of antihistamines are as follows: Central Nervous System: Sedation and sleepiness (often transient), dizziness, disturbed coordination, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, paresthesias, neuritis, convulsions, euphoria, hallucinations, hysteria, faintness. Integumentary: Allergic manifestation of rash and edema, excessive perspiration, urticaria, photosensitivity. Special Senses: Acute labyrinthitis, blurred vision, diplopia, vertigo, tinnitus. Cardiovascular: Hypotension, palpitation, tachycardia, extrasystoles, anaphylactic shock. …

Do not use if

Newborn or Premature Infants: This drug should not be used in newborn or premature infants. Nursing Mothers: Because of the higher risk of antihistamines for infants generally, and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. Other Conditions: Hypersensitivity to cyproheptadine and other drugs of similar chemical structure. Monoamine oxidase inhibitor therapy (see DRUG INTERACTIONS ). Angle-closure glaucoma. Stenosing peptic ulcer. …

Warnings

Children - Overdosage of antihistamines, particularly in infants and children, may produce hallucinations, central nervous system depression, convulsions, and death. Antihistamines may diminish mental alertness conversely particularly in the young child they may occasionally produce excitation. CNS Depressants - Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. Activities Requiring Mental Alertness - Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery. …

Pregnancy & breastfeeding

PREGNANCY Pregnancy Category B: Reproduction studies have been performed in rabbits, mice, and rats at oral or subcutaneous doses up to 32 times the maximum recommended human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to cyproheptadine. Cyproheptadine has been shown to be fetotoxic in rats when given by intraperitoneal injection in doses four times the maximum recommended human oral dose. …

General information only, not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Inkretin Tablets

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Inkretin Tablets

What is in Inkretin Tablets?

Inkretin Tablets contains Cyproheptadine Hydrochloride (4 mg), as tablet, according to its NAFDAC registration record.

Is Inkretin Tablets registered with NAFDAC?

Yes. Inkretin Tablets is listed on the NAFDAC register under registration number A11-100728, and its registration is active as of 28 October 2026.

Has Inkretin Tablets been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Inkretin Tablets in our automatically synced alert list.

How can I check that my pack of Inkretin Tablets is genuine?

Run a free authenticity scan with the NAFDAC number A11-100728, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Inkretin Tablets used for?

Perennial and seasonal allergic rhinitis, Vasomotor rhinitis, Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Cold urticaria. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute man (Summarised from the official U.S. FDA label for cyproheptadine hydrochloride. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Inkretin Tablets? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.